Characterization of p97 mutations causing multisystem proteinopathy support a gain-of-function model for pathology

Valosin‐containing protein (VCP, or p97) is an ATPase essential in numerous protein quality control (PQC) pathways, such as ER‐associated degradation. p97 functions as a segregase, extracting ubiquitylated proteins from membranes or complexes so they can be degraded by the proteasome. However, the complexity of native p97 PQC substrates has stymied the detailed biochemical study of this function. Previously, to address this problem, we developed an in vitro p97 substrate based on an ubiquitin fusion degradation (UFD) pathway substrate, Ub‐GFP, and showed that the unfolding of this substrate by p97 is dependent upon extensive substrate ubiquitylation, the p97 adaptors NPLOC4‐UFD1L, and ATP hydrolysis. Here, we make use of this system, employing an updated version of this substrate, to explore how mutations in p97 that cause multisystem proteinopathy (MSP) affect substrate processing. Previous studies have shown that MSP mutants have higher basal ATP rates than wild type yet cause deficiencies in many p97‐dependent pathways, creating controversy as to whether these dominantly inherited mutations cause disease through a gain‐of‐function or a loss‐of‐function. We have now analyzed seven distinct MSP mutants, all of which showed modestly improved unfolding of our model substrate over wild type p97, providing evidence that the increased ATPase activity leads to a gain‐of‐function. Furthermore, we showed evidence that p97 inhibitors may restore proper p97 function to MSP mutants, suggesting a potential treatment strategy for p97 diseases

Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy

p97 is a “segregase” that plays a key role in numerous ubiquitin (Ub)-dependent pathways such as ER-associated degradation. It has been hypothesized that p97 extracts proteins from membranes or macromolecular complexes to enable their proteasomal degradation; however, the complex nature of p97 substrates has made it difficult to directly observe the fundamental basis for this activity. To address this issue, we developed a soluble p97 substrate—Ub-GFP modified with K48-linked ubiquitin chains—for in vitro p97 activity assays. We demonstrate that WT p97 can unfold proteins and that this activity is dependent on the p97 adaptor NPLOC4-UFD1L, ATP hydrolysis, and substrate ubiquitination, with branched chains providing maximal stimulation. Furthermore, we show that a p97 mutant that causes inclusion body myopathy, Paget’s disease of bone, and frontotemporal dementia in humans unfolds substrate faster, suggesting that excess activity may underlie pathogenesis. This work overcomes a significant barrier in the study of p97 and will allow the future dissection of p97 mechanism at a level of detail previously unattainable

Characterization of p97 mutations causing multisystem proteinopathy support a gain-of-function model for pathology

Valosin‐containing protein (VCP, or p97) is an ATPase essential in numerous protein quality control (PQC) pathways, such as ER‐associated degradation. p97 functions as a segregase, extracting ubiquitylated proteins from membranes or complexes so they can be degraded by the proteasome. However, the complexity of native p97 PQC substrates has stymied the detailed biochemical study of this function. Previously, to address this problem, we developed an in vitro p97 substrate based on an ubiquitin fusion degradation (UFD) pathway substrate, Ub‐GFP, and showed that the unfolding of this substrate by p97 is dependent upon extensive substrate ubiquitylation, the p97 adaptors NPLOC4‐UFD1L, and ATP hydrolysis. Here, we make use of this system, employing an updated version of this substrate, to explore how mutations in p97 that cause multisystem proteinopathy (MSP) affect substrate processing. Previous studies have shown that MSP mutants have higher basal ATP rates than wild type yet cause deficiencies in many p97‐dependent pathways, creating controversy as to whether these dominantly inherited mutations cause disease through a gain‐of‐function or a loss‐of‐function. We have now analyzed seven distinct MSP mutants, all of which showed modestly improved unfolding of our model substrate over wild type p97, providing evidence that the increased ATPase activity leads to a gain‐of‐function. Furthermore, we showed evidence that p97 inhibitors may restore proper p97 function to MSP mutants, suggesting a potential treatment strategy for p97 diseases

PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network

Co-opting Cullin4 RING ubiquitin ligases (CRL4s) to inducibly degrade pathogenic proteins is emerging as a promising therapeutic strategy. Despite intense efforts to rationally design degrader molecules that co-opt CRL4s, much about the organization and regulation of these ligases remains elusive. Here, we establish protein interaction kinetics and estimation of stoichiometries (PIKES) analysis, a systematic proteomic profiling platform that integrates cellular engineering, affinity purification, chemical stabilization, and quantitative mass spectrometry to investigate the dynamics of interchangeable multiprotein complexes. Using PIKES, we show that ligase assemblies of Cullin4 with individual substrate receptors differ in abundance by up to 200-fold and that Cand1/2 act as substrate receptor exchange factors. Furthermore, degrader molecules can induce the assembly of their cognate CRL4, and higher expression of the associated substrate receptor enhances degrader potency. Beyond the CRL4 network, we show how PIKES can reveal systems level biochemistry for cellular protein networks important to drug development

p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates

Glutamine synthetase (GS) plays an essential role in metabolism by catalyzing the synthesis of glutamine from glutamate and ammonia. Our recent study showed that CRBN, a direct protein target for the teratogenic and antitumor activities of immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide, recognizes an acetyl degron of GS, resulting in ubiquitylation and degradation of GS in response to glutamine. Here, we report that valosin-containing protein (VCP)/p97 promotes the degradation of ubiquitylated GS, resulting in its accumulation in cells with compromised p97 function. Notably, p97 is also required for the degradation of all four known CRBN neo-substrates [Ikaros family zinc finger proteins 1 (IKZF1) and 3 (IKZF3), casein kinase 1α (CK1α), and the translation termination factor GSPT1] whose ubiquitylation is induced by immunomodulatory drugs. Together, these data point to an unexpectedly intimate relationship between the E3 ubiquitin ligase CRL4^(CRBN) and p97 pathways

Role of Predicted Metalloprotease Motif of Jab1/Csn5 in Cleavage of Nedd8 from Cul1

COP9 signalosome (CSN) cleaves the ubiquitin-like protein Nedd8 from the Cul1 subunit of SCF ubiquitin ligases. The Jab1/MPN domain metalloenzyme (JAMM) motif in the Jab1/Csn5 subunit was found to underlie CSN's Nedd8 isopeptidase activity. JAMM is found in proteins from archaea, bacteria, and eukaryotes, including the Rpn11 subunit of the 26S proteasome. Metal chelators and point mutations within JAMM abolished CSN-dependent cleavage of Nedd8 from Cul1, yet had little effect on CSN complex assembly. Optimal SCF activity in yeast and both viability and proper photoreceptor cell (R cell) development in Drosophila melanogaster required an intact Csn5 JAMM domain. We propose that JAMM isopeptidases play important roles in a variety of physiological pathways

Multisystem Proteinopathy Mutations in VCP/p97 Increase NPLOC4·UFD1L Binding and Substrate Processing

Valosin-containing protein (VCP)/p97 is an essential ATP-dependent protein unfoldase. Dominant mutations in p97 cause multisystem proteinopathy (MSP), a disease affecting the brain, muscle, and bone. Despite the identification of numerous pathways that are perturbed in MSP, the molecular-level defects of these p97 mutants are not completely understood. Here, we use biochemistry and cryoelectron microscopy to explore the effects of MSP mutations on the unfoldase activity of p97 in complex with its substrate adaptor NPLOC4⋅UFD1L (UN). We show that all seven analyzed MSP mutants unfold substrates faster. Mutant homo- and heterohexamers exhibit tighter UN binding and faster substrate processing. Our structural studies suggest that the increased UN affinity originates from a decoupling of p97's nucleotide state and the positioning of its N-terminal domains. Together, our data support a gain-of-function model for p97-UN-dependent processes in MSP and underscore the importance of N-terminal domain movements for adaptor recruitment and substrate processing by p97

Multisystem Proteinopathy Mutations in VCP/p97 Increase NPLOC4·UFD1L Binding and Substrate Processing

Valosin-containing protein (VCP)/p97 is an essential ATP-dependent protein unfoldase. Dominant mutations in p97 cause multisystem proteinopathy (MSP), a disease affecting the brain, muscle, and bone. Despite the identification of numerous pathways that are perturbed in MSP, the molecular-level defects of these p97 mutants are not completely understood. Here, we use biochemistry and cryoelectron microscopy to explore the effects of MSP mutations on the unfoldase activity of p97 in complex with its substrate adaptor NPLOC4⋅UFD1L (UN). We show that all seven analyzed MSP mutants unfold substrates faster. Mutant homo- and heterohexamers exhibit tighter UN binding and faster substrate processing. Our structural studies suggest that the increased UN affinity originates from a decoupling of p97's nucleotide state and the positioning of its N-terminal domains. Together, our data support a gain-of-function model for p97-UN-dependent processes in MSP and underscore the importance of N-terminal domain movements for adaptor recruitment and substrate processing by p97

Gal4 turnover and transcription activation

Growing evidence supports the notion that proteasome-mediated destruction of transcriptional activators can be intimately coupled to their function. Recently, Nalley et al. challenged this view by reporting that the prototypical yeast activator Gal4 does not dynamically associate with chromatin, but rather 'locks in' to stable promoter complexes that are resistant to competition. Here we present evidence that the assay used to reach this conclusion is unsuitable, and that promoter-bound, active Gal4 is indeed susceptible to competition in vivo. Our data challenge the key evidence that Nalley et al. used to reach their conclusion, and indicate that Gal4 functions in vivo within the context of dynamic promoter complexes